Incidence Rates for Anal Carcinoma, Adenocarcinoma Have Increased Significantly
the Cancer Therapy Advisor take:
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The authors of the study used data from the Surveillance, Epidemiology and End Results (SEER) Program to estimate age-adjusted anal cancer IRs by demographic and tumor characteristics from 2000 to 2011. Trends in annual percent changes and IRs from 1977 to 2011 were compared to those of rectal cancer.
Results showed females were associated with higher rates of SCC (rate ratio [RR]=1.45; 95% CI: 1.40, 1.50) and lower rates of ADC (RR=0.68; 95%CI: 0.62, 0.74) and squamous carcinoma in situ (CIS; RR=0.36; 95%CI: 0.34, 0.38) compared to males.
Furthermore, African Americans demonstrated lower rates of SCC (RR=0.82; 95% CI: 0.77, 0.87) and CIS (RR=0.90; 95% CI: 0.83, 0.98) but higher rates of ADC (RR=1.48; 95% CI 1.29-1.70) compared to non-Hispanic whites.
From 1992 to 2011, SCC IRs increased 2.9% per year, ADC IRs declined non-significantly, and CIS IRs increased 14.2% per year.
The authors noted similar trends were observed in SCC and ADC IRs across anal and rectal cancers.
Incidence rates of anal squamous cell carcinoma and squamous carcinoma in situ have significantly increased overtime.
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer